One-carbon therapeutics AB is tackling the most difficult to treat cancers, inflammation and autoimmune diseases by targeting the disease specific one-carbon metabolism pathway, representing a novel way of attacking the DNA damage response (DDR). Here is the place where create innovative precision oncology medicines are born.
Co-founded in 2020 by the Helleday Laboratory, with over 20 years of experience in DNA damage response (DDR) biology, we are taking the previous success of discovering the synthetic lethal concept for the treatment of BRCA mutated cancer with PARP inhibitors to a new level; attacking difficult to treat cancers using synthetic lethality in the one-carbon pathway to target the DNA damage response for treatment of cancer and inflammation.
At One-carbon therapeutics we apply cutting-edge science to create first-in-class treatments against MTHFD1/2 cancer proteins and related targets. Our development is guided by advanced biomarkers identified using primary cancer patient’s tumors.
Cancer cells alter their metabolic pathways to meet the increased demand for energy and building blocks needed for rapid cell proliferation and survival. Yet, these alterations come with a cost of increased DNA damage that, if left unrepaired, will lead to cancer cell death. For this reason, cancer cells rely heavily on DNA damage response (DDR) pathways to maintain genome integrity. Targeting these pathways is a common approach to treating cancer. More recently, compelling findings indicate a connection between cancer metabolism and DNA damage repair processes. Metabolic enzymes represent a crucial group of factors within the DDR, opening novel ways to target these cancer vulnerabilities therapeutically.
Many years of experience in oncology drug discovery and development, identified and brought first-in-class DDR targets to clinical trials. The co-founder of One-carbon therapeutics pioneered the PARP-BRCA synthetic lethal concept.
Building on frontline research and developing first-in-class treatments for a new emerging area within the DDR space. Advanced structure-guided medicinal chemistry and unique mechanism of action.
Targeting cancers with high unmet clinical need using state-of-the-art ex vivo screening and defined biomarker-driven patient selection. Employing emerging ex vivo screening methods for increased accuracy.
Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, announced today the closing of an oversubscribed 153 million
Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering a novel cancer therapy, today announced that the first subject has been successfully dosed